JY
SYRE icon

Jeff Yass’s Spyre Therapeutics SYRE Stock Holding History

Jeff Yass’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.8M Buy
155,200
+68,800
+80% +$5.02M ﹤0.01% 2911
2026
Q1 		$4.36M Buy
86,400
+72,400
+517% +$2.73M ﹤0.01% 4490
2025
Q4 		$459K Buy
+14,000
New +$366K ﹤0.01% 8997
2025
Q2 		– Sell
-47,000
Closed -$759K – 13693
2025
Q1 		$759K Buy
+47,000
New +$978K ﹤0.01% 7948
2023
Q1 		– Sell
-408
Closed -$4.59K – 13477
2022
Q4 		$4.59K Buy
+408
New +$7.33K ﹤0.01% 12057

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jeff Yass's SYRE Position: Q2 2026 in Review

Jeff Yass increased its Spyre Therapeutics (SYRE) stake by 36% in Q2 2026, buying an estimated $755K and bringing the position to 39,311 shares worth $3.49M. The position accounts for ﹤0.01% of the portfolio, ranked #5321.

Jeff Yass first reported a position in SYRE in Q2 2017 and has held it in 18 quarters since. The position peaked at $3.85M in Q1 2024. 263 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Jeff Yass held 39,311 shares of Spyre Therapeutics worth $3.49M as of Q2 2026.
  • Jeff Yass bought 10,349 Spyre Therapeutics shares in Q2 2026, an estimated $755K.
  • Spyre Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5321 holding.
  • Jeff Yass first reported a position in Spyre Therapeutics in Q2 2017 and has held it in 18 quarters since.
  • Jeff Yass's Spyre Therapeutics position peaked at $3.85M in Q1 2024.
  • 263 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.